Clinical Research Papers:

Dexmedetomidine attenuates acute paroxysmal sympathetic hyperactivity

Yuan Peng, Haifeng Zhu, Haodong Chen, Zijin Zhu, Huahai Zhou, Shuguang Zhang, Lili Gao, Lei Shi, Xiaoliang Li and Zhengxiang Luo _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:69012-69019. https://doi.org/10.18632/oncotarget.16920

Metrics: PDF 1612 views  |   HTML 2282 views  |   ?  


Yuan Peng1,*, Haifeng Zhu2,*, Haodong Chen3,*, Zijin Zhu4,*, Huahai Zhou5,*, Shuguang Zhang1,*, Lili Gao2, Lei Shi1,*, Xiaoliang Li1 and Zhengxiang Luo6

1Department of Intensive Care Unit and Neurosurgery, The First People’s Hospital of Kunshan Affiliated with Jiangsu University, Suzhou 215300, P. R. China

2Department of Neurosurgery and Medical Oncology, Jiangsu Funing People’s Hospital, Funing 224400, P. R. China

3Department of Neurosurgery, Liuhe Hospital Affiliated to Medical College of Yangzhou University, Nanjing 211500, P. R. China

4Department of Neurosurgery, Anhui Province Wangjiang Hospital, Anhui 246200, P. R. China

5Department of Neurosurgery, Sihong County People’s Hospital, Suqian 223900, P. R. China

6Department of Neurosurgery, Nanjing Brain Hospital Affiliated to Nanjing Medical University, Nanjing 210029, P. R. China

*These authors have contributed equally to this work

Correspondence to:

Zhengxiang Luo, email: [email protected]

Keywords: dexmedetomidine, propofol, paroxysmal sympathetic hyperactivity, prognosis

Abbreviations: PSH, paroxysmal sympathetic hyperactivity; α2-AR, α2-adrenoceptor; GCS, Glasgow Coma Scale; PAID, paroxysmal autonomic instability with dystonia

Received: February 13, 2017    Accepted: March 20, 2017    Published: April 07, 2017


We evaluated the curative effect of dexmedetomidine on paroxysmal sympathetic hyperactivity (PSH) in a retrospective study of 72 PSH patients after neurosurgery. Our results showed that dexmedetomidine was superior to propofol for treatment of PSH with respect to: average time needed to reduce paroxysmal hypertension (PH) to <140/90 mmHg (29.03±8.86 vs. 42.0±14.77 min), average remission time of PH (3.97±1.73 vs. 5.65±1.51 min), PH remission rate (61.22±10.8% vs. 41.52±14.15%), PH duration (9.31±2.66 vs. 13.05±4.19 days), average time for body temperature to return to normal (10.62±4.14 vs. 15.31±4.58 days), average time for heartrate to return to normal (11.34±3.90 vs. 15.72±4.10 days), and average time of respiratory rate below 25 breaths per minute (BPM) (7.00±1.74 vs. 15.32±5.87 days). Multiple logistic regression analyses showed that dexmedetomidine did not protect against the recurrence of PSH. Age and Glasgow Coma Score were the main factors predicting PSH recurrence. There was no difference in Glasgow Outcome Score (GOS) between the two groups during the 6 months of postoperative follow-up (p>0.05). These data suggest dexmedetomidine effectively controls an acute attack of PSH, but it does not improve the long-term prognosis of patients compared with propofol.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16920